Cargando…
Mechanistic advances in osteoporosis and anti‐osteoporosis therapies
Osteoporosis is a type of bone loss disease characterized by a reduction in bone mass and microarchitectural deterioration of bone tissue. With the intensification of global aging, this disease is now regarded as one of the major public health problems that often leads to unbearable pain, risk of bo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175743/ https://www.ncbi.nlm.nih.gov/pubmed/37188325 http://dx.doi.org/10.1002/mco2.244 |
_version_ | 1785040277128347648 |
---|---|
author | Wang, Haiwei Luo, Yuchuan Wang, Haisheng Li, Feifei Yu, Fanyuan Ye, Ling |
author_facet | Wang, Haiwei Luo, Yuchuan Wang, Haisheng Li, Feifei Yu, Fanyuan Ye, Ling |
author_sort | Wang, Haiwei |
collection | PubMed |
description | Osteoporosis is a type of bone loss disease characterized by a reduction in bone mass and microarchitectural deterioration of bone tissue. With the intensification of global aging, this disease is now regarded as one of the major public health problems that often leads to unbearable pain, risk of bone fractures, and even death, causing an enormous burden at both the human and socioeconomic layers. Classic anti‐osteoporosis pharmacological options include anti‐resorptive and anabolic agents, whose ability to improve bone mineral density and resist bone fracture is being gradually confirmed. However, long‐term or high‐frequency use of these drugs may bring some side effects and adverse reactions. Therefore, an increasing number of studies are devoted to finding new pathogenesis or potential therapeutic targets of osteoporosis, and it is of great importance to comprehensively recognize osteoporosis and develop viable and efficient therapeutic approaches. In this study, we systematically reviewed literatures and clinical evidences to both mechanistically and clinically demonstrate the state‐of‐art advances in osteoporosis. This work will endow readers with the mechanistical advances and clinical knowledge of osteoporosis and furthermore present the most updated anti‐osteoporosis therapies. |
format | Online Article Text |
id | pubmed-10175743 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101757432023-05-13 Mechanistic advances in osteoporosis and anti‐osteoporosis therapies Wang, Haiwei Luo, Yuchuan Wang, Haisheng Li, Feifei Yu, Fanyuan Ye, Ling MedComm (2020) Reviews Osteoporosis is a type of bone loss disease characterized by a reduction in bone mass and microarchitectural deterioration of bone tissue. With the intensification of global aging, this disease is now regarded as one of the major public health problems that often leads to unbearable pain, risk of bone fractures, and even death, causing an enormous burden at both the human and socioeconomic layers. Classic anti‐osteoporosis pharmacological options include anti‐resorptive and anabolic agents, whose ability to improve bone mineral density and resist bone fracture is being gradually confirmed. However, long‐term or high‐frequency use of these drugs may bring some side effects and adverse reactions. Therefore, an increasing number of studies are devoted to finding new pathogenesis or potential therapeutic targets of osteoporosis, and it is of great importance to comprehensively recognize osteoporosis and develop viable and efficient therapeutic approaches. In this study, we systematically reviewed literatures and clinical evidences to both mechanistically and clinically demonstrate the state‐of‐art advances in osteoporosis. This work will endow readers with the mechanistical advances and clinical knowledge of osteoporosis and furthermore present the most updated anti‐osteoporosis therapies. John Wiley and Sons Inc. 2023-05-11 /pmc/articles/PMC10175743/ /pubmed/37188325 http://dx.doi.org/10.1002/mco2.244 Text en © 2023 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Wang, Haiwei Luo, Yuchuan Wang, Haisheng Li, Feifei Yu, Fanyuan Ye, Ling Mechanistic advances in osteoporosis and anti‐osteoporosis therapies |
title | Mechanistic advances in osteoporosis and anti‐osteoporosis therapies |
title_full | Mechanistic advances in osteoporosis and anti‐osteoporosis therapies |
title_fullStr | Mechanistic advances in osteoporosis and anti‐osteoporosis therapies |
title_full_unstemmed | Mechanistic advances in osteoporosis and anti‐osteoporosis therapies |
title_short | Mechanistic advances in osteoporosis and anti‐osteoporosis therapies |
title_sort | mechanistic advances in osteoporosis and anti‐osteoporosis therapies |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175743/ https://www.ncbi.nlm.nih.gov/pubmed/37188325 http://dx.doi.org/10.1002/mco2.244 |
work_keys_str_mv | AT wanghaiwei mechanisticadvancesinosteoporosisandantiosteoporosistherapies AT luoyuchuan mechanisticadvancesinosteoporosisandantiosteoporosistherapies AT wanghaisheng mechanisticadvancesinosteoporosisandantiosteoporosistherapies AT lifeifei mechanisticadvancesinosteoporosisandantiosteoporosistherapies AT yufanyuan mechanisticadvancesinosteoporosisandantiosteoporosistherapies AT yeling mechanisticadvancesinosteoporosisandantiosteoporosistherapies |